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Abstract Protein C inhibitor (PCI) is the plasma serine
protease inhibitor of activated protein C, the active enzyme of
the anticoagulant protein C pathway. Recently, PCI was also
detected in human seminal plasma and reproductive organs
(testis, seminal vesicle and prostate) suggesting that PCI may
also play an important role in the reproductive system. In this
study, we cloned the full length of rat PCI cDNA, and
determined its amino acid sequence and tissue distribution. We
also evaluated the effect of androgen on PCI mRNA expression
in seminal vesicles and testes. The isolated 2074-bp rat PCI
cDNA was composed of a 47-bp 5P-non-coding region, a 1218-bp
coding region of a 406-amino acid precursor protein, a stop
codon and a 806-bp 3P-non-coding region. The deduced amino
acid sequence of rat PCI showed 85.7%, 64.1% and 62.2%
homology with that of mouse, rhesus monkey and human PCIs,
respectively. Northern blot analysis showed that the rat PCI
mRNA is expressed strongly in the seminal vesicle, moderately in
the testis, but not in the liver. PCI mRNA expression in seminal
vesicles and testes was found to increase during the process of
development, suggesting that it is under androgen control.
Subsequently, we examined the effect of castration and/or
treatment with 17L-estradiol or testosterone on PCI mRNA
expression in the mature rat seminal vesicles. The PCI mRNA
expression in seminal vesicles was significantly decreased after
castration or 17L-estradiol treatment. Testosterone itself did not
affect PCI mRNA expression, but treatment in castrated rats
significantly enhanced its mRNA expression. These findings
suggest that the PCI gene expression in rat seminal vesicles is
regulated by androgen.
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1. Introduction
Protein C inhibitor (PCI) is a member of the plasma serine
protease inhibitor (serpin) family proteins. It was originally
described as an inhibitor of the anticoagulant protease, acti-
vated protein C [1], and subsequently found to inhibit a vari-
ety of other proteases involved in blood coagulation and ¢-
brinolysis, such as thrombin [2], thrombin-thrombomodulin
complex [3], factor Xa [2], factor XIa [4], plasma kallikrein
[4] and urokinase-type plasminogen activator (uPA) [5]. Re-
cently, human PCI was also detected in various extracellular
£uids, its concentration being particularly high in seminal
plasma [6], and it was found to inhibit several serine proteases
involved in the process of reproduction (e.g. prostate-speci¢c
antigen (PSA) [7] and sperm acrosin [8]).
Human PCI is synthesized in the liver, kidney and in male
reproductive organs (e.g. testis, seminal vesicle and prostate).
Interestingly, the level of PCI in seminal plasma was found to
be low in some infertile men [6]. Moreover, PCI was reported
to inhibit the binding of human sperm to the oocyte; in this
binding, a site other than the reactive site of PCI is involved
[9,10]. Recently, we reported that seminal plasma PCI e¡ec-
tively inhibits PSA by forming a complex with it, and that
PCI binds to the seminal coagula proteins, semenogelins I and
II, protecting them from degradation by proteases [11]. These
observations suggest that PCI participates in the regulation of
reproduction.
PCI cDNAs of human [12] and rhesus monkey [13] were
previously isolated and characterized. Human PCI gene con-
sists of ¢ve exons and four introns [14,15]. This genetic or-
ganization is similar to that of other members of the serpin
family such as K1-antitrypsin [16], K1-antichymotrypsin [17]
and heparin cofactor II [18]. The mouse PCI gene was also
recently reported to have the same gene organization, and its
amino acid sequence was described to be highly homologous
to that of human PCI [19]. Interestingly, mouse PCI mRNA is
only expressed in organs of the reproductive system such as
testis, seminal vesicle and ovary, but not in the liver [20].
These reports also suggest that PCI plays a role in the regu-
lation of the reproductive system.
In the present study, we cloned the rat PCI cDNA and
characterized its structure and distribution in di¡erent rat
tissues. We also assessed the hormonal regulation of PCI
mRNA in seminal vesicles and testes. The results suggest
that PCI mRNA expression in the seminal vesicles is regulated
by androgen.
2. Materials and methods
2.1. Ampli¢cation of partial cDNA encoding mouse PCI using
polymerase chain reaction (PCR)
A sense primer located in exon III (5P-GTATTCCTACTACCTG-
GACC-3P, nucleotide residues 2124^2143) and an antisense primer in
exon V (5P-CAGCTGCTGTGGTTCCTGAC-3P, complementary to
nucleotide residues 4121^4102) of the genomic DNA of mouse PCI
[19] were prepared and reverse transcriptase (RT)-PCR was per-
formed. Reverse transcription was done using the T-Primed First-
Strand kit (Pharmacia, Uppsala, Sweden) with 5 Wg of total RNA
isolated from the testes of BALB/c mice by standard protocol [21].
Using 1 Wg of this ¢rst-strand cDNA as a template, PCR ampli¢ca-
FEBS 20377 18-6-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 6 1 3 - 9
*Corresponding author. Fax: (81) (59) 231-5209.
E-mail: suzuki@doc.medic.mie-u.ac.jp
Abbreviations: PCI, protein C inhibitor; Serpin, serine protease
inhibitor; PSA, prostate-specific antigen; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; EIA, enzyme immunoassay; uPA, uroki-
nase-type plasminogen activator
FEBS 20377 FEBS Letters 429 (1998) 263^268
tion was conducted during 35 cycles (94‡CU1 min, 58‡CU1 min,
72‡CU2 min) using Taq polymerase (TaKaRa Shuzo, Kyoto, Japan)
and a thermal cycler (model 480; Perkin-Elmer, Norwalk, CT, USA)
[22]. PCR products were then subcloned into pBluescript SKII (Stra-
tagene, La Jolla, CA, USA) and sequenced using Dye Terminator
Cycle Sequencing FS Ready Reaction kit and ABI 373A DNA se-
quencer (PE Applied Biosystems, Cheshire, UK) [23]. The mouse PCI
cDNA fragment prepared in this way was then used as a probe for
screening the rat testes cDNA library.
2.2. Cloning of rat PCI cDNA
The VZAP II rat testes cDNA library (Stratagene) was screened
using a probe prepared from a portion of the mouse PCI cDNA
(368 bp), as described above. Screening was performed as described
previously [24]. Bacteriophage plaques giving positive hybridization
signals were re-screened and puri¢ed. Isolated VZAP clones were con-
verted into pBluescript SK3 phagemid clones by in vivo excision,
according to the manufacturer’s instruction.
2.3. DNA sequence analysis
Phagemid DNAs were digested with EcoRI, and Southern blot
hybridization was performed as described previously [25]. The
cDNA clones were cleaved by several restriction endonucleases (Bam-
HI, EcoRI, HindIII, KpnI, and PstI), and both strands of the cDNA
clones were sequenced by primer walking using ABI 373A DNA se-
quencer.
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Fig. 1. Comparison of the deduced amino acid sequences of the PCI precursor protein of four species. Amino acid numbering is based on the
amino-terminal residue of rat PCI precursor protein (position +1). Conserved amino acids in four species are enclosed within open boxes. The
estimated amino-terminal amino acid residue (Arg20) of the rat mature protein is marked by an asterisk, the estimated glycosylation sites of rat
PCI are indicated by shaded boxes and the reactive site of PCI is indicated by an arrow.
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2.4. Animals
Wistar rats used in this study were housed under a constant 12-h
light and 12-h dark cycle, and were allowed free access to standard
food and water. Adult male and female rats (9 weeks old; body
weight 180^200 g) were used to study the tissue distribution of PCI
mRNA. Male rats from 2 to 9 weeks old (each age group n = 3) were
used to study the PCI mRNA expression in seminal vesicles and testes
during development. Adult male rats (9 weeks old) were classi¢ed into
six groups (each group n = 3): (a) castrated rats under pentobarbital
anesthesia, (b) sham-operated rats but without removal of the testes,
(c) rats receiving daily subcutaneous injections of 1 mg of testosterone
propionate (Sigma, St. Louis, MO, USA) on days 4^12 after castra-
tion, rats treated with daily subcutaneous injections of (d) 100 Wg of
17L-estradiol (Sigma), (e) 1 mg of testosterone propionate, or (f) ve-
hicle alone (i.e. 200 Wl of olive oil). Three rats were killed by overdose
injection of pentobarbital on days 2, 4, 6 and 8 after the treatments.
In case of groups a and c, the rats were killed using the same method
used on days 10 and 12 after castration. The dose of hormone was the
same as reported in a previous study [26]. Seminal vesicles and testes
of the rats were removed and immediately frozen in liquid nitrogen
and then stored at 380‡C. These samples were used for the extraction
of total RNA and for Northern blot analysis. At the same time,
citrated plasma of each rat was also prepared and stored at 330‡C;
plasma samples were then used to measure the levels of testosterone.
2.5. RNA extraction and Northern blot analysis
Frozen tissue samples (kidney, liver, lung, brain, heart, small intes-
tine, colon, ovary, testis, prostate, seminal vesicle, spleen and uterus)
were homogenized in RNAzol B (TEL-TEST, Friendswood, TX,
USA), without thawing. Total RNA was then extracted by a modi¢-
cation of the method of Chomczynski and Sacchi [21], and quanti-
tated spectrophotometrically. Northern blot analysis was carried out
as follows. Total RNA (20 Wg for analysis of the tissue distribution of
PCI or for studying the change of PCI mRNA expression in testes
after treatment, and 10 Wg for studying the change of PCI mRNA
expression in seminal vesicles after treatment) of each tissue sample
was electrophoresed in formaldehyde-agarose gels, transferred onto
GeneScreen nylon membranes (NEN Life Science, Boston, MA,
USA), UV cross-linked, and hybridized with full-length rat PCI
cDNA probe as described previously [24]. The membrane was exposed
to imaging plate and analyzed using BAS-2000 Image Analyzer (Fuji
Photo Film, Tokyo, Japan). After hybridizing with rat PCI cDNA
probe, the membranes were boiled in 0.5% sodium dodecyl sulfate and
rehybridized with 32P-labeled human glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) cDNA probe (Clontech, Palo Alto, CA,
USA) to correct di¡erences in loading or transfer e⁄ciency of RNA
in di¡erent lanes. In each lane, the ratio between the relative inten-
sities of the PCI mRNA band and the GAPDH band was evaluated
using BAS-2000 Image Analyzer; the ratios were used to compare the
PCI mRNA levels of di¡erent lanes.
2.6. Measurement of testosterone concentration in rat plasma
Testosterone concentration in rat plasma was measured using tes-
tosterone enzyme immunoassay (EIA) kit (Cayman Chemical, Ann
Arbor, MI, USA) according to the manufacturer’s instruction.
3. Results
3.1. Cloning and characterization of rat PCI cDNA
Fourteen independent clones were isolated by screening
6U105 plaques of VZAP II rat testes cDNA library. The
plaques were then converted into pBluescript SK3 phagemid
clones by in vivo excision. Southern blot analysis of the
cDNA inserts showed that they consisted of three types of
fragments. As the sequence analysis of their 5P- and 3P-ends
demonstrated that two smaller fragments were completely in-
cluded in the largest one, the nucleotide sequence of both
strands of the largest fragment was determined, and it was
found to contain a 2074-bp nucleotide sequence which en-
codes a 47-bp 5P-non-coding region, a 406-amino acid precur-
sor protein, a stop codon and a 806-bp 3P-non-coding region.
The nucleotide sequence data reported in this paper will
appear in the DDBJ/EMBL/GenBank nucleotide sequence
databases with accession number AB013128.
3.2. Comparison of the amino acid sequence of rat PCI with
that of mouse, rhesus monkey and human PCIs
Fig. 1 shows the amino acid sequence of the rat PCI pre-
cursor protein deduced from its cDNA, and the alignment of
the sequence of precursor protein of rat PCI with that of
mouse, rhesus monkey and human PCIs. The precursor pro-
tein of rat PCI was composed of 406 amino acid residues
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Fig. 2. Tissue distribution of rat PCI mRNA. Total RNA (20 Wg)
isolated from various tissues was analyzed by Northern blot analysis
using 32P-labeled rat PCI cDNA or GAPDH cDNA as a probe.
Fig. 3. Change of PCI mRNA expression in seminal vesicles and
plasma testosterone levels during development. A: Total RNA (10
Wg) isolated from seminal vesicles of each age was analyzed by
Northern blotting using 32P-labeled rat PCI cDNA or GAPDH as a
probe. Radioactivity of the band corresponding to PCI mRNA and
GAPDH mRNA was measured by Image Analyzer as photostimu-
lated luminescence value (PSL), and the ratio of PSL of PCI
mRNA to that of GAPDH mRNA was calculated; the ratio ob-
tained in 9-week-old rats was taken as 100%. Plasma testosterone
levels of each age group of rats were measured using the testoster-
one EIA kit. Data are expressed as mean þ S.D. (n = 3). (b) relative
PCI mRNA levels, (O) plasma testosterone levels. B: One typical
data point of PCI mRNA and GAPDH mRNA expression of each
age group.
T. Wakita et al./FEBS Letters 429 (1998) 263^268 265
identical to that of rhesus monkey and human PCIs, but not
to that of mouse PCI consisting of 405 amino acid residues.
The amino acid sequence of rat PCI showed 85.7%, 64.1%
and 62.2% of homology with that of mouse, rhesus monkey
and human PCIs, respectively. In the amino acid sequence of
the rat PCI precursor protein, the putative reactive site (P1-
P1P) at Arg372-Ser373, the potential O-glycosylation sites at
Ser57, and the potential N-glycosylation site at Asn248 were
estimated. Like mouse, rhesus monkey and human PCIs, the
putative reactive site at Arg372-Ser373 was located in the same
amino acid sequence from P1 to P3P. One cysteine residue at
Cys251 next to the potential N-glycosylation site in rat PCI
was conserved in three other species’ PCIs. Two potential
glycosylation sites located at amino acid residues Ser57 and
Asn248 were also conserved in all species.
3.3. Tissue distribution of rat PCI mRNA
Expression of PCI mRNA in various rat tissues was ana-
lyzed by Northern blotting. As shown in Fig. 2, the PCI
mRNA (approximately 2.1 kb in size) was expressed strongly
in the seminal vesicle and moderately in the testis, but not in
the liver and other tissues. The lack of PCI mRNA expression
in the liver and other tissues was not the result of RNA
degradation, because GAPDH mRNA remained almost in-
tact.
3.4. PCI mRNA expression in rat seminal vesicles and testes
during development
Fig. 3A,B shows that PCI mRNA is not expressed in semi-
nal vesicles of 2-week-old rats. However, PCI mRNA expres-
sion level gradually increased during development, and this
increase was associated with concomitant changes in the plas-
ma level of testosterone. The PCI mRNA expression in testes
during development was similar to that in seminal vesicles
(data not shown). This ¢nding suggests that the increase of
PCI mRNA expression in seminal vesicles and testes may be
under androgen control during the process of development.
3.5. E¡ect of castration or sex hormone treatment on PCI
mRNA expression in rat seminal vesicles and testes
PCI mRNA levels in seminal vesicles of rats treated with
testosterone showed no di¡erence compared with those of un-
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Fig. 4. E¡ect of castration on PCI mRNA expression in seminal
vesicles and on plasma testosterone levels. A: Total RNAs (10 Wg)
isolated from seminal vesicles of sham-operated (a) or castrated
rats (b) were analyzed by Northern blotting using 32P-labeled rat
PCI cDNA or GAPDH cDNA as a probe. Relative PCI mRNA
levels were obtained as described in the legend to Fig. 3. Plasma
testosterone levels of sham-operated rats (O) and castrated rats (R)
were measured using the testosterone EIA kit. Data are expressed
as the mean þ S.D. (n = 3). B: One typical data point of PCI mRNA
and GAPDH mRNA expression of sham-operated or castrated rats.
Fig. 5. E¡ect of testosterone replacement on PCI mRNA expression
in seminal vesicles and on plasma testosterone levels. A: Total
RNAs (10 Wg) isolated from seminal vesicles of castrated rats (a) or
of castrated rats treated daily with testosterone (b) from day 4 after
castration were analyzed by Northern blotting using 32P-labeled rat
PCI cDNA or GAPDH cDNA as a probe. Relative PCI mRNA
levels were obtained as described in the legend to Fig. 3. Plasma
testosterone levels of castrated rats (O) and castrated rats treated
with testosterone (R) were measured using the testosterone EIA kit.
Data are expressed as mean þ S.D. (n = 3). The arrow indicates the
day when testosterone was injected. B: One typical data point of
PCI mRNA and GAPDH mRNA expression of castrated or cas-
trated and testosterone-treated rats.
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treated rats (data not shown). In addition, PCI mRNA ex-
pression in testes of rats treated with 17L-estradiol did not
signi¢cantly change as compared with untreated rats (data
not shown). However, as shown in Fig. 4A,B, castration re-
sulted in a time-dependent decrease of PCI mRNA expression
in rat seminal vesicles. On day 2 after castration, PCI mRNA
levels in seminal vesicles were signi¢cantly (P6 0.005) de-
creased as compared to those in sham-operated rats, the max-
imum e¡ect being observed on day 4 after castration. This
decrease of PCI mRNA levels after castration was associated
with parallel changes in the plasma testosterone levels. The
administration of 17L-estradiol also resulted in a time-depend-
ent decrease of PCI mRNA expression in seminal vesicles. On
day 2 after 17L-estradiol treatment, PCI mRNA levels in
seminal vesicles and plasma testosterone levels were signi¢-
cantly decreased in treated rats as compared with untreated
rats (data not shown). These data suggest that PCI mRNA
expression in seminal vesicles may be regulated by testoster-
one.
To con¢rm this, the e¡ect of testosterone replacement on
PCI mRNA expression in seminal vesicles of castrated rats
was examined. Fig. 5A,B indicates that PCI mRNA levels in
seminal vesicles maximally decreased on day 4 after castra-
tion, but they increased signi¢cantly by daily administration
of testosterone. These data indicate that, in our experimental
conditions, testosterone regulates the expression of PCI
mRNA in rat seminal vesicles.
4. Discussion
The deduced amino acid sequence of the rat PCI precursor
protein showed that the putative reactive site and the site of
cysteine residue of human [12], rhesus monkey [13] and mouse
[19] PCIs are well-conserved in rat PCI. In addition, a possible
heparin-binding site of the mature human PCI located be-
tween residues 264 and 283 (these residues are located between
residues 283 and 302 in human PCI precursor protein as
shown in Fig. 1) [27,28] appears to be conserved between
residues 282 and 301 of the rat PCI precursor protein; seven
positively charged residues are present in human PCI and ¢ve
in rat PCI. However, it remains unclear whether rat PCI ac-
tually binds to heparin. On the other hand, the potential gly-
cosylation sites in PCI seem to be di¡erent. Human and rhe-
sus monkey PCIs have three N-glycosylation sites (Asn249,
Asn262 and Asn338) and two O-glycosylation sites (Thr39 and
Ser58) [12,13], but rat PCI has only one N-glycosylation site
(Asn248) and two O-glycosylation sites (Ser57 and Ser373 ; the
latter is not reasonable because this site is involved in the
reactive site). The di¡erences of the glycosylation sites be-
tween the two types of PCI may in£uence the speci¢city of
the inhibitor towards the target proteases, their stability in
body £uids, and/or the speci¢city of their tissue expression.
The present analysis showed that the rat PCI mRNA is
expressed only in the male reproductive system (seminal
vesicle and testis). These observations encouraged us to assess
whether PCI expression in seminal vesicles and testes is regu-
lated by sex hormones. The fact that PCI mRNA expression
in the seminal vesicles and testes was gradually increased dur-
ing rat development (from 2 to 9 weeks old) suggests that rat
PCI mRNA expression is in£uenced by androgen. The e¡ect
of castration or 17L-estradiol treatment on PCI mRNA ex-
pression in rat seminal vesicles suggests that PCI gene expres-
sion is under androgen control in seminal vesicles. Testoster-
one replacement in castrated rats also showed that PCI
mRNA expression in seminal vesicles depends on the level
of testosterone. Although 17L-estradiol did not signi¢cantly
a¡ect PCI mRNA expression in rat testes, this was probably
due to the small amount of endogenous testosterone released
by Leydig cells; this basic level of testosterone probably stim-
ulates constantly PCI mRNA expression in the testes. Long-
term administration of 17L-estradiol may down-regulate PCI
gene expression in the testes. On the other hand, testosterone
itself did not appear to a¡ect the PCI mRNA expression in
seminal vesicles and testes, so that the excess amount of tes-
tosterone may not a¡ect target organs. The partial structure
of the human PCI gene has already been reported [14,15],
however there is no androgen-responsive element [29] in the
1.6-kb 5P-non-coding region of the human PCI gene [30].
Several proteases such as acrosin and uPA have been re-
ported to participate in the process of reproduction. Acrosin,
which is released from mammalian sperm during the acroso-
mal reaction, plays a fundamental role in the mechanism of
sperm penetration into the zona pellucida [31]. uPA is ex-
pressed by epithelial cells from male genital organs (e.g. semi-
nal vesicle, cauda epididymidis and vas deferens) and it is
secreted during ejaculation to bind the sperm surface [32,33].
uPA has been suggested to play an important role in sperm
capacitation and fertilization processes. The regulatory mech-
anisms of the proteolytic activity of these enzymes in the
reproductive system are not completely understood. It has
been suggested that a member of the serpin family, protease
nexin I, may inhibit uPA activity in the reproductive system
[34]. PCI, another component of the serpin family, is func-
tionally and immunologically the same as plasminogen acti-
vator inhibitor-3 [35], which is known to e¡ectively inhibit
uPA activity [5]. In addition, PCI has also been reported to
modulate the proteolytic activity of acrosin and PSA; this
latter is suggested to be an important factor for sperm motil-
ity and fertilization. All together, these ¢ndings suggest that
PCI may play an important function in the regulation of
proteolytic processes in the reproductive system.
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